Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The United Laboratories International Holdings ( (HK:3933) ) has provided an announcement.
The United Laboratories International Holdings Limited has entered into an exclusive license agreement with Novo Nordisk for the development and commercialization of UBT251, a triple agonist targeting GLP-1, GIP, and glucagon receptors, for treating obesity, type 2 diabetes, and other diseases. This agreement allows Novo Nordisk worldwide rights, excluding certain regions, and includes potential payments up to $1.8 billion plus royalties, highlighting a significant strategic partnership that could enhance the company’s market position and financial performance.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a leading integrated pharmaceutical company in China, engaged in the research, development, production, and sales of pharmaceuticals. It operates seven production bases and has a sales network in nearly 80 countries. United Biotechnology, a subsidiary, focuses on developing high-end biopharmaceuticals for major chronic diseases.
YTD Price Performance: 28.57%
Average Trading Volume: 13,212
Technical Sentiment Signal: Sell
Current Market Cap: $3.66B
Find detailed analytics on 3933 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue